Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURP Combined with Standard Systemic Therapy in Metastatic Prostate Cancer
NCT06655259Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Metastatic Prostate Cancer (mPC), sponsored by Fudan University. Primary endpoints: Radiographic Progression-Free Survival at 2 years and Urinary Symptom Relief Rate at 2 years. Started Sep 2024; status: recruiting.
02
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT06655259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655259.